JASUBHAI GROUP      ABOUT CHEMTECH     ADVISORY BOARD     AWARDS       EVENTS     PUBLICATIONS     CONTACTUS    
Chemical & Processing
EPC
Oil & Gas
Refining
Automation
Pharma Biotech
Shipping
Power
Water
Infrastructure & Design

"We aim to sharpen our product offerings while ensuring innovation and keeping pace with industry trends"
TAKE Solutions Ltd embarked on a fiveyear transformational scale-up plan with a mission to significantly magnify its size and scale, amplifying its revenues by five-time to emerge as an USD 500 million enterprise. Ram Yeleswarapu, President & CEO, TAKE Solutions elucidates more on this in an email interaction with with Mahesh Kallayil.
Ram Yeleswarapu,
President & CEO,
Take Solutions
"Clearsynth adheres to the changing requirements by introducing advanced mechanisms and instruments"
"Clearsynth intends to be the catalyst in accelerated discovery via synthesis of complex and difficult to make compounds. The company is dedicatedly developing future molecules to meet the requirements of pharmaceutical industry and targeting new sectors such as enzymes, natural extracts, vitamins, hormones and petrochemicals." Says Vijay Ambati, President & CEO, Clearsynth. Excerpts from the interview he had with Mahesh Kallayil.
Vijay Ambati,
President & CEO,
Clearsynth.
The ‘Standard’ Way of Doing Business
During 2016, the Standard Group of Companies posted business growth of 34 per cent over 2015 and anticipates much of the same growth in 2017 and 2018. This should deliver a modest ` 500 crores/year sales turnover by the end of 2021 which is pretty impressive given their standing start just a few years ago. During an interview with K Nageswara Rao, Group Managing Director, Standard Group, it becomes clear that the Standard Group is following anything but a ‘standard’ business model.
K Nageswara Rao,
Group Managing Director, Standard Group,
“We stay abreast of the developments in genomics on a regular basis by incorporating the most recent published research in this domain”
With exper tise in precision medicine and personalized preventive Health, Xcode believes that the era of “one size fits all” in medicine is over. Competing with other global players, Xcode is working closely with professional practitioners across domains to enable truly personalized solutions across the spectrum of human needs. Dr Abdur Rub, Co-founder, Xcode Life Sciences, in an interview with Mahesh Kallayil discusses the evolving role of genomics and personalized medicine in Indian pharma industry and much more.
Dr Abdur Rub
Co-founder, Xcode Life Sciences,
“Innoplexus is not just a business but a mission to create an impact”
Innoplexus focuses on product development for Big Data Analytics. The company helps in the future of how data is curated, analyzed and consumed by disrupting prevailing processes through cutting edge technology, innovation and a superlative ability to understand business challenges. Dr Gunjan Bharadwaj, Founder and Chairman, Innoplexus shares his Views on Data Analytics scenario in India and Globally and How Data analytics is enhancing accuracy and cost cutting in Pharma and Lifescience sector, in an email interaction with Mahesh Kallayil.
DR GUNJAN BHARADWAJ,
Founder and Chairman.
“Our regular interaction has led to industry- friendly steps initiated by the Government”
“A more proactive interaction between enforcement agencies and stakeholders such as Industry, trade, chemists and doctors on a regular basis is missing and this would help in recognising early trends of drug abuse and putting in control mechanisms to prevent the same”, says Daara B Patel, Secretary- General, IDMA. In an exclusive interview with Mahesh Kallayil, he elucidates the inaccurate information surrounding Ephedrine and Pseudoephedrine and NDPS (Narcotic Drugs and Psychotropic Substances).
Daara B Patel,
Secretary- General,IDMA.
”Our accrued expertise over the period of time helps us to be effective in the evolving industrial demands”
“Green manufacturing approaches in pharmaceuticals assumes prime importance due to its sheer size as well as the overall alleviation effect it potentially brings to already stressed environmentally nonbenign chemical process”, says Satish Varma, Managing Director, Fermenta Biotech Limited. In an interview with Mahesh Kallayil, he further discusses Indian Biopharma market, Fermenta’s journey so far, future plans and many more. Excerpts from the interview.
Satish Varma,
Managing Director, Fermenta Biotech Limited
“We launched Safyr specifically to meet requirements of India's domestic pharmaceutical packaging market”
“Globally, innovation is recognized by governments and corporations alike as the fundamental driver of economic and business growth. In India, however, the links between innovation in industry, academia and government is still in a nascent stage,” says Arvind Pachhapur South Asia Head - Intellectual Property & Science and Legal Business, Thomson Reuters. In an interview with Mahesh Kallayil, he further discusses how the linkages between Industry-Academia-Government is a tool to achieve economic growth.
Arvind Pachhapur,
South Asia Head - Intellectual Property & Science and Legal Business, Thomson Reuters.
“We launched Safyr specifically to meet requirements of India's domestic pharmaceutical packaging market”
Scott Gaddis, Global Business Leader, Healthcare Products, Honeywell shares his insights on Safyr, a high-moisture barrier thermoformable film recently launched by Honeywell and company’s commitment towards developing industry leading packaging solutions that can deliver increased competitive advantage, in an email interaction with Mahesh Kallayil.
Scott Gaddis,
Global Business Leader, Healthcare Products, Honeywell
“We act as a portal for the global players to enter Indian market and vice versa”
Voisin Consulting Life Sciences (VCLS), the global healthcare product development consultancy recently acquired B&H Consulting Services, Inc (B&H), an experienced regulatory firm helping pharma and biotech companies facilitate interactions with FDA and navigate the regulatory process, forming one of the World’s Largest Independent Life Sciences Consulting Groups. In a tête-à-tête with Mahesh Kallayil, Emmanuelle M Voisin, Founder and CEO, VCLS deliberates on potential of the deal and her observations on Indian biopharma market, while Rajashree Devarakonda, Vice President - India and Asia Pacific, VCLS talks about Voisin’s operations in India, challenges and opportunities for Indian biopharma companies and many more. Excerpts from the interview…
Emmanuelle M Voisin,
Founder and CEO, VCLS
“Nanoparticle-based drug delivery can improve the safety and efficacy of existing drugs”
Dr Robert Langer was the first person to engineer polymers to control the delivery of large molecular weight drugs for the treatment of diseases such as cancer and mental illness. In an exclusive email interaction with Mahesh Kallayil, Dr Langer shares his insights on chemical engineering and its application in biopharma and the trends he observes in India.
- Dr Robert Langer
“Pharma should start treating investments in IT as a prerequisite rather than a luxury”
“The predominant ly generic Indian pharmaceutical industry has been voraciously adopting technology solutions, more than ever before,” says Ram Yeleswarapu, President and Chief Executive Officer, TAKE Solutions. Excerpts from an interview Yeleswarapu had with Mahesh Kallayil.
Ram Yeleswarapu,
President and Chief Executive Officer, TAKE Solutions
“It is a good sign that the US and Indian regulators are collaborating on inspections”
Kate Kuhrt Senior Director, Proposition, Generics and Biotech, Thomson Reuters in an interview with Mahesh Kallayil discusses the evolution of Global and Indian Generic Industry in next few years.
Kate Kuhrt,
Senior Director, Proposition, Generics and Biotech, Thomson Reuters
NGS is a Natural Evolution from Early Methods
Dr David Dunn, Practice Consultant in the Life Sciences and Professional Services Group, Thomson Reuters in an interview with Mahesh Kallayil shares strategies for Biosimilars in the Regulated and Emerging Markets.
Dr David Dunn
“We created a niche for ourselves in Indian Pharma Market based on our innovative technology”
HRS Process Systems operates at the forefront of thermal processing technology and is one of the leading heat exchanger specialists catering to pharma industry offering energy ef ficient and hygenic solutions for an extensive range of applications. V Gokuldas, Managing Director, HRS Process Systems Ltd in an interview with Mahesh Kallayil discusses more on this.
V Gokuldas,
Managing Director, HRS Process Systems Ltd
“We have a culture that encourages creative thinking and views failure as learning experience”
With the recent acquisition of US-based Coldstream Laboratories, Piramal Pharma Solutions has transformed into a full service sterile contract development and manufacturing organization offering end to end solution to customers. Vivek Sharma, CEO- Pharma Solutions, Piramal Enterprises Ltd in conversation with Mahesh Kallayil, talks about the company’s key milestones, growth strategies, market trends and challenges.
Vivek Sharma,
CEO- Pharma Solutions, Piramal Enterprises Ltd
“In the Right Direction”
“We are looking at clocking 30-35 per cent annual growth from the Indian market,” shared Friedbert Klefenz, President, Bosch Packaging Technology. In an exclusive interview, he talked about the Company’s Vision 2020, maintaining the position amongst the market leaders and the plans to offer complete line solutions for customers across global markets with Mittravinda Ranjan on the side lines of ACHEMA 2015 in Frankfurt, Germany.
Friedbert Klefenz,
President, Bosch Packaging Technology.
“Strong patent laws will encourage innovation in the research based pharmaceutical industry”
Ranjana Smetacek, Director General, Organisation of Pharmaceutical Producers of India (OPPI), in an exclusive interview with Mahesh Kallayil talks about the need for strong IP law and balancing innovation with access and affordability of medicine.
Ranjana Smetacek,
Director General, Organisation of Pharmaceutical Producers of India (OPPI)
“India need to improve the regulatory milieu to compete with other Asian countries”
Dr Subir Basak, President, Jubilant Drug Discovery and Development Services in an interview with Pharma Bio World discusses emerging role of CROs in Indian pharmaceutical market
Dr Subir Basak,
President, Jubilant Drug Discovery and Development Services
Pages » 1 2 3